Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has recently been recognized as one of the 13 Companies that Just Started Paying Dividends. The company, led by CEO Leonard Schleifer, reported steady revenue growth during the Q4 2025 earnings call. Fourth-quarter sales increased by 3% compared to the previous year, driven by double-digit growth in three key products.
Global net sales of DUPIXENT surged by 32%, while LIBTAYO sales saw a 13% increase on a constant-currency basis. In the U.S., EYLEA HD sales stood out with a remarkable 66% growth. Schleifer highlighted the strong performance of these products, especially in the domestic market, signaling positive momentum for the company.
DUPIXENT, described as a core pillar of the business, is now being used by over 1.4 million patients worldwide and is poised for further growth. Progress at LIBTAYO was also emphasized, with strength in adjuvant CSCC and a growing market share in advanced non-small cell lung cancer. In the U.S., the therapy has become the second most prescribed immunotherapy in the first-line setting.
Looking ahead, Schleifer outlined an ambitious regulatory and development agenda for Regeneron Pharmaceuticals. The company anticipates at least four FDA approvals, including three new molecular entities across different modalities, as well as approval of the EYLEA HD prefilled syringe. Additionally, plans are in place to launch 18 additional Phase III studies over the coming years, with an estimated total enrollment of around 35,000 patients. This significant investment aims to support the development of potential blockbuster products in the future.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company that focuses on inventing, developing, manufacturing, and commercializing medicines for individuals with serious diseases.
While Regeneron shows promise as an investment opportunity, some experts believe that certain AI stocks may offer greater upside potential with lower downside risk. For investors seeking an undervalued AI stock that could benefit from current economic trends, a free report on the best short-term AI stock is available.
In conclusion, Regeneron Pharmaceuticals continues to make strides in the biotechnology industry with its innovative products and strategic development plans. Investors should keep an eye on the company’s future advancements and potential growth opportunities.
Disclosure: None.
